Member Info for LovableLumax

I suspect if Avacta announces DX sold and funds sufficient to have audit signed off, P1b has started and read out still this year I suspect the share price will improve. We’ll have complete P1A read out too, P1b design and who knows once DX sold may improve the share register with specialist TX investors. Paying 3m or so shares each Q as we did for a long time was fine. So no to a discounted raise for CLN as I don’t believe it’s needed once other things are delivered.

It was subject to an RNS but an RNS reach as the partnership is not deemed material. The NOMAD would have spoken to mirriad re projected 12 month revenue and if not expected to be 10% of last year’s revenue it is not worthy of a regulated RNS but a reach RNS. Come March 1st mirriad will have burnt another £1m so wil have less than £4m cash. If they need to raise cash (highly likely) surely it happens in March. Any later and the discount will be even worse.

Have you sold Bentley or will sell as I think you had 10m or so. If you are going to sell maybe better to hope for some volume to sell into (like what our Abcam founder did recently). According to some on here there is an afternoon US buyer although with no TR1s and recent volume it looks unlikely.

Good luck either way.

I won’t second guess the FDA but if the data is knock out who knows. A superb safety profile so fewer side effects and better efficacy than alternatives (no standard of care) and who knows. Dox is dox so I suspect the other two arms will also be very strong. I’d like a takeover which will be lower than during P2 but a major should take preCISION and come P1b conclusion will be 150 patients dosed and lots of data.

If P1b data is superb it’s not beyond the realms that Salivary gland cancer is quickly approved. No standard of care and with 40 patients as we already have 10 with a 90% disease control (when all disease was progressing hence they stopped prior treatments) if there are impressive results I am sure things will move quickly. Emerging data likely too.

Deary me the saddo pretending he doesn’t read my posts. What a joke. He slyly replies to my posts. Creepy James.

Yes Avacta is at 45p some 10% below the 50p raise. Not sure what your point is when you had a fit and accused the BoD and broker of a mates rates raise and it needs to double a fair few times to get to 1.25p. I mean revenues of £1m FFS. The CEO takes half that in his package!!!

i’m always happy to admit when i’m wrong. i didn’t know there was a 30 day rule. that being the case it doesn’t mean what phevs is saying it’s total bull****. if a holder thought the share price was going up they wouldn’t sell and certainly not when nearly 2 months of the tax year left.

all the tr1s have been sales. bizarre given the awful share price.

Phevs comes out with all sorts of crap to support his narrative. The only TR1s we've had since the raise TR1s are for sells, if memory serves 4 of them. Phevs said the most recent one was to mitigate capital gains (he got the wrong tax year for Abcam sale but hey) and thinks the large rollover trade is something similar. Look at the identical number and a slight increase in the second one, rollover clear as day. In any case does the clown not realise the UK's tax year is early April so why the feck would someone sell now and not the last day of tax year to solidify loss and then buy them back the following day? It's embarrassing how dumb he is.

Who knows this might come good and if it does it will explode. History suggests another raise imminent. Come March 1st Mirriad will likely have less cash than the last time they started work on the raise last year (mid April).

So I guess phevs realises the super bowl chat is more mindless ramping. Given the pathetic revenue per campaign mirriad has been getting for its streaming work the money on influencer campaigns won't cover their monthly wifi bill.

I remember phevs telling everyone mirriad was working on Yellowstone, pah, more BS

These links don’t mean mirriad placed the ads. I remember you doing the same on Yellowstone and I pointed out that the brands will work with various agencies and media planners and buyers. The revenue suggests I was right and mirriad hod nothing to do with Yellowstone. Same is likely to apply here. Any ads worth 10% of revenue have to have an RNS. A superbowl ad would cost in excess of that so it’s clearly not mirriad placing it.

*That's near to what they had in May when the last raise went through (although it was worked on in April).

Let's assume MIRI has a decent 3 months and come the end of March they have £3.5m cash left. That's near to what they had in May when the last raise went through. If the above is near to a good guide they would be crazy to not ask for cash beforehand as the less cash they have the worse the deal will be. Of course they could get a lot of booked campaigns which should mean less cash needed. All these LinkedIn posts are immaterial as the last few yeas have shown, lots of LinkedIn 'research' posted on here with ever impressive endorsements all the while revenues drop. The last set of KPIs should be a concern.

MIRI can't leave a raise until the end of May as most upfronts mid May.

In TV advertising, the "Upfront" is the long-established practice of buying and selling TV advertising time months in advance, typically in the Spring of each year, for advertising space scheduled to air in the coming television broadcast year. The most significant of these events is the US Network Upfronts, an annual, weeklong event in New York.

Balance is always good. Ideally Wyn would use fewer words and his posts seem to ramble on!

Most CEOs and CFOs take the view to position a co. as solidly as pos ahead of a potential buy out to extract as much value as pos. A huge number of PLCs get taken over soon after raising cash. Given the amount of efficacy data in a safety trial I expect P1b to have a large amount of impressive results in 90 patients and I expect some serious moves then. Beforehand have a decent enough cash runway and once P1b published (assuming dox continues to behave as it has on dox sensitive tumours) and options aplenty

Avacta would be crazy to sell/license 6103 for example. If 6000 is amazing for an orphan indication in P1b there could be relatively fast approval and revenues coming in. Yes 6103 a way off but a major could take it through a route quickly and that will eat into 6000’s revenue and will have a much much bigger market. It could be the most successful cancer therapy there is. Point is it doesn’t make sense giving away such an asset to a competitor. Ideally get amazing P1b data and sell the lot. In the meantime the co needs to communicate as the silence deafening. It’s frustrating but hopefully the 6 patients whose disease stabilised or regressed with SGC are still improving. Who knows what discussion re 6000 are happening but news needed.

So Stephan's son is very successful and must be pretty wealthy. Bizarre then that he didn't take any shares in the raise or indeed is buying any all the way down here. I guess he isn't for the same reason as the rest of thew BOD isn't.

Nilesh this happens on many stocks where the spread isn't really tight, less common on MAIN market PLCs. It's simply a buy below mid price will show as a sell and a sell above mid price will show as a buy. There's no conspiracy.

Wyn I suspect they will publish emerging data. We have seen tumour regression after just 2 cycles so we could get data as early as April. Given what we know so far unless 6000 suddenly fails P1b will be knock out. Many lives extended I’m sure.

I cannot see more dilution before P1b results. I wager DX with existing cash will enable audit sign off and once P1b published options aplenty back end of the year.

Who knows Mirriad might have a strategic investor who will take shares to get them through the audit or may really accelerate revenue growth, who knows but the notion that directors are in a closed period due to new clients is nonsense. Shopify was secured last year and wasn't material so no RNS which is obvious given the paltry revenues and looking at the KPIs you can see the number of campaigns and brands represented which shows they're worth very little. There have been months without material RNSs and the reason this BOD has never bought in the open market is not due to being unable to. The next month or so make or break.